Pliant Therapeutics Inc (PLRX) - Total Liabilities
Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has total liabilities worth $37.43 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pliant Therapeutics Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Pliant Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Pliant Therapeutics Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Pliant Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Pliant Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sun Max Tech Ltd
TW:6591
|
Taiwan | NT$1.33 Billion |
|
Daidong Elec
KO:008110
|
Korea | ₩25.54 Billion |
|
Hannan Metals Ltd
V:HAN
|
Canada | CA$200.47K |
|
Dominari Holdings Inc.
NASDAQ:DOMH
|
USA | $53.74 Million |
|
DocCheck AG
XETRA:AJ91
|
Germany | €14.07 Million |
|
Sempio Foods Co
KO:248170
|
Korea | ₩132.99 Billion |
|
Sinkang Industries Co Ltd
TW:2032
|
Taiwan | NT$586.66 Million |
|
Westwater Resources Inc
NYSE MKT:WWR
|
USA | $13.00 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Pliant Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pliant Therapeutics Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pliant Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pliant Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Pliant Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $44.02 Million | -52.60% |
| 2024-12-31 | $92.87 Million | +140.73% |
| 2023-12-31 | $38.58 Million | +3.51% |
| 2022-12-31 | $37.27 Million | +68.22% |
| 2021-12-31 | $22.16 Million | +77.75% |
| 2020-12-31 | $12.46 Million | -89.57% |
| 2019-12-31 | $119.50 Million | +77.27% |
| 2018-12-31 | $67.41 Million | +2014.52% |
| 2017-12-31 | $3.19 Million | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more